PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

NCT00611793 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Refractory Malignancy
Advanced Malignancies

Interventions

DRUG: PTK787/ZK222584 and Bevacizumab

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]